Fig. 1: Genomic landscape of PTEN in glioblastoma patients.
From: Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma
A Genomic landscape of PTEN in glioblastoma (GBM) in the study cohort. B Mutation profiles of PTEN alterations in GBM tumors. Statistically significant association between mutation type and PTEN domain was identified; missense mutations were dominant in the phosphatase domain, while truncating mutations were prevalent in the C2 domain (p-value < 0.001, Fisher’s exact test). C Survival outcome of GBM patients stratified by PTEN alteration status. There was no statistically significant difference in prognosis as a function of the alteration status of PTEN (p-value = 0.1, Log-rank test). Survival analysis was performed using Kaplan–Meier method and log-rank test was used to statistically compare the curves. cnv, copy-number variation; mut, mutation; no., number; OS, overall survival; WT, wild-type; DEL-only, deletion only; MUT-only, mutation only; both, both mutation and deletion alleles.
